Skip to main content
Triangle logo TriangleGet started

PDS01ADC (NCT05361798)

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy: a one-minute explainerNCT053617981 min

PDS01ADC trial for Cancer Of Prostate (NCT05361798). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult men with localized intermediate- or high-risk prostate cancer who need stereotactic radiation and androgen deprivation. Previous prostate surgery, focal therapy or radiation is excluded.

The idea: everyone receives radiation and hormone suppression. Selected groups also receive three PDS01ADC injections four weeks apart. This antibody-linked IL-12 signal targets exposed DNA in dying tumor areas, aiming to stimulate immune activity. Researchers assess safety and T-cell changes.

This phase 2 study plans 65 patients. The ceiling includes screen failures. Melissa Abel leads at NIH in Bethesda, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.